Lung cancer combo therapy shows promise in High-Risk patients
NCT ID NCT04547504
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This phase 3 trial compares two first-line treatments for advanced non-small-cell lung cancer with high PDL1 levels (50% or more). About 349 participants receive either pembrolizumab alone or pembrolizumab plus chemotherapy. The goal is to see if the combination delays cancer progression better than the single drug, especially for patients at risk of early worsening.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hôpital Cochin
Paris, 75014, France
-
CH Intercommunal de Créteil
Créteil, 94010, France
-
CH La Roche Sur Yon - CHD Les Oudairies
La Roche-sur-Yon, 85000, France
-
CH La Réunion - Site Félix Guyon
Saint-Denis, 97400, France
-
CH MEAUX
Meaux, 77108, France
-
CH d'Annecy-genevois
Pringy, 74374, France
-
CH de Lorient - Hôpital du Scorff
Lorient, 56100, France
-
CH du Pays d'Aix
Aix-en-Provence, 13616, France
-
CHRU de Brest
Brest, 29609, France
-
CHU AMIENS - Hôpital Sud
Amiens, 80054, France
-
CHU Bordeaux - Hôpital du Haut Levêque
Pessac, 33604, France
-
CHU La Réunion - Groupe Hospitalier Sud
Saint-Pierre, 97410, France
-
CHU MARSEILLE_ Hopital Nord
Marseille, 13915, France
-
CHU RENNES - Hôpital Pontchailloux
Rennes, 35033, France
-
CHU ROUEN - Hôpital Charles Nicolle
Rouen, 76031, France
-
Centre Hospitalier Métropole Savoie
Chambéry, 73000, France
-
Centre Hospitalier de Cornouaille
Quimper, 29000, France
-
Centre Léon Berard
Lyon, 69008, France
-
Centre de lutte contre le cancer - Centre François Baclesse
Caen, 14000, France
-
Ch Villefranche Sur Saone
Villefranche-sur-Saône, 69655, France
-
Chu Angers
Angers, 49033, France
-
Chu Dupuytren
Limoges, 87042, France
-
Hôpital Européen Marseille
Marseille, 13003, France
-
Hôpital d'Instruction des Armées Toulon - Saint Anne
Toulon, 83041, France
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Institut Paoli-Calmette
Marseille, 13000, France
-
Institut de Cancérologie Strasbourg Europe
Strasbourg, 67200, France
-
SAINT-PRIEST EN JAREZ - Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, 42271, France
-
Saint Aubin Les Elbeuf
Saint-Aubin-lès-Elbeuf, 76503, France
Conditions
Explore the condition pages connected to this study.